Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy(Chinese PLA General Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy(Chinese PLA General Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers
9 min read
Red cell units that are genotype matched at the RHD and RHCE loci(Children's Hospital of Philadelphia) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Red cell units that are genotype matched at the RHD and RHCE loci(Children's Hospital of Philadelphia): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review
9 min read
Adipose-derived multipotent mesenchymal stem cells(Guangdong Hospital of Traditional Chinese Medicine) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Adipose-derived multipotent mesenchymal stem cells(Guangdong Hospital of Traditional Chinese Medicine): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review
9 min read
Super Hi-TCR-T Cells Targeting Nectin4/NKG2DL/TROP2/B7H3/GPC3/FAP(Eastern Hepatobiliary Surgery Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Super Hi-TCR-T Cells Targeting Nectin4/NKG2DL/TROP2/B7H3/GPC3/FAP(Eastern Hepatobiliary Surgery Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence revi
9 min read
ALN-6457 (Regeneron Pharmaceuticals, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
ALN-6457 (Regeneron Pharmaceuticals, Inc.): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market pos
9 min read
K-13 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
K-13: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
HUMSCs combined with bovine type I collagen(The First Affiliated Hospital of Xinxiang Medical College) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
HUMSCs combined with bovine type I collagen(The First Affiliated Hospital of Xinxiang Medical College): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review
9 min read
Humanized anti-EGFR monoclonal antibody(Henan Shengming Biotechnology Research Institute Co Ltd) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Humanized anti-EGFR monoclonal antibody(Henan Shengming Biotechnology Research Institute Co Ltd): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers
9 min read
Base-edited hematopoietic stem and progenitor cells(National Institute of Allergy & Infectious Diseases) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Base-edited hematopoietic stem and progenitor cells(National Institute of Allergy & Infectious Diseases): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence revie
9 min read
Lentiviral vector transduced CD34+ cells(Great Ormond Street Hospital for Children NHS Foundation Trust) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Lentiviral vector transduced CD34+ cells(Great Ormond Street Hospital for Children NHS Foundation Trust): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence revie
9 min read
CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers cli
9 min read
Autologous Bone Marrow Mesenchymal Stem Cell Therapy(Nantong Shengyuan Stem Cell Techology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Autologous Bone Marrow Mesenchymal Stem Cell Therapy(Nantong Shengyuan Stem Cell Techology): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clin